Twyman-Saint et al. found that in clinical melanoma trials, patients with high programmed death-ligand 1 (PD-L1) did not respond to anti-CTLA4 plus radiation and depicted persistent T cell failure, but the combination of anti-CTLA4, anti-PD-L1, and radiation could promote immune responses. The gene discussed is CD274; the disease is melanoma.